Latest Conference Articles

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

Pain improvement was associated with remission or low disease activity in patients undergoing treatment for rheumatoid arthritis, a study found.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses the hopeful future of treatment in idiopathic hypersomnia.

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.

An interview with Mark Lanasa, MD, PhD, BeiGene senior vice president and chief medical officer for solid tumors, conducted at ASCO 2024.

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in the annual ASCO recap issue of Evidence-Based Oncology.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

A study finds limited changes in hospice utilization, highlighting challenges in real-world implementation.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.

Experts share their biggest takeaways from the European Hematology Association (EHA) 2024 Congress.

Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.

Enthusiasm abounded at the recent European Hematology Association 2024 Congress about whether European regulators will begin to consider minimal residual disease (MRD) as an end point.

A poster presented at the 2024 American Society of Clinical Oncology annual meeting argued the benefits that Medicaid expansion can bring to patients with melanoma.

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases.

The late-breaking oral session at the European Hematology Association (EHA) 2024 Congress featured new data from abstracts submitted after the deadline, including both interventional and foundational science.

Mohamad Mohty, MD, PhD, of Saint-Antoine Hospital and Sorbonne University, highlights how immunotherapies are offering various effective treatment options for patients with multiple myeloma and improving quality of life for relapsed/refractory patients.

Joseph Mikhael, MD, MEd, FRCPC, FACP, of the International Myeloma Foundation, HonorHealth, and TGen, notes that US physicians have more flexibility when treating patients with early relapsed/refractory multiple myeloma, whereas those in Europe must follow stricter protocols.

At a session of the European Hematology Association 2024 Congress, presenters shared updates from trials of treatment strategies for newly diagnosed multiple myeloma (MM).

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases.

At a friendly debate held at the European Hematology Association 2024 Congress, hemophilia experts argued for and against wider access to gene therapy for patients living with the condition.

Ryan Jacobs, MD, of Atrium Health Levine Cancer Institute, explains that the phase 2 CAPTIVATE study's fixed-duration treatment cohort shows long-term progression-free survival for patients with chronic lymphocytic leukemia (CLL) who received the first-line treatment of ibrutinib and venetoclax.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.